Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00210626 · ClinicalTrials.gov registry record · Phase 2
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT00210626 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 192 participants.
The verdict
NCT00210626, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the physical function outcomes in anemic, critically ill, trauma subjects treated with epoetin alfa (PROCRIT®) compared to placebo.
Interventions
- DRUG Placebo
- DRUG PROCRIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00210626
The ClinicalTrials.gov registry entry for NCT00210626 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00210626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00210626 about?
NCT00210626 is a clinical study titled "Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa". The purpose of this trial is to evaluate the physical function outcomes in anemic, critically ill, trauma subjects treated with epoetin alfa (PROCRIT®) compared to placebo.
What is the current status of trial NCT00210626?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2005-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00210626?
The interventions under investigation include: Placebo (DRUG), PROCRIT (DRUG).
Who is sponsoring clinical trial NCT00210626?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.